Ocular Therapeutix, Inc.
Health
Performance
7.5
Risk
Sell
Buy
Curious about the Scores? Learn more.

Ocular Therapeutix, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

17.07.2026
Breaking down. The red game over screen is flashing.
10.07.2026
Losing steam. Not trending your way right now.
13.06.2026
Off life support. Still risky, but slightly less scary.
OCUL
Ocular Therapeutix, Inc.
8.99
+3.16%
7.5
Sell
Buy
Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Ocular Therapeutix, Inc. do? Business model and key facts

Get the full picture of Ocular Therapeutix, Inc.: what it builds, where it operates, and how it makes money.

Ocular Therapeutix, Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 325

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

shop
Company facts
Pravin U. Dugel
CEO
325
Employees worldwide
shop
Performance
-24.39%
Last 12 months
-29.53%
Last 5 years
shop
Growth
$51.82M
Revenue year
$-265,939,000
Net income
shop
Valuation
$1.96B
Market Cap
-8.55
Price/Earnings Ratio

Stocks related to Ocular Therapeutix, Inc.

Selected based on industry alignment and relative market positioning.

ABCL
AbCellera Biologics Inc.
5.95
+2.59%
8.8
Sell
Buy
AbCellera Biologics Inc.
ADMA
ADMA Biologics, Inc.
8.66
-1.09%
8.8
Sell
Buy
ADMA Biologics, Inc.
AUPH
Aurinia Pharmaceuticals Inc.
15.55
+1.93%
6.6
Sell
Buy
Aurinia Pharmaceuticals Inc.
HRMY
Harmony Biosciences Holdings, Inc.
36.60
+9.24%
6.7
Sell
Buy
Harmony Biosciences Holdings, Inc.
BCRX
BioCryst Pharmaceuticals, Inc.
9.37
+2.85%
5.0
Sell
Buy
BioCryst Pharmaceuticals, Inc.

Events and news impacting Ocular Therapeutix, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Ocular Therapeutix, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.